Table 1

Treatment in the MAINTAIN Nephritis Trial Cohort at 10 years of follow-up*

All (n=87)MMF group (n=42)AZA group (n=45)p Value†
Follow-up (months; median/range)110/18–156105/18–156114/18–1520.80
Age at follow-up (years; median/range)42±1042±942±100.84
Currently on GC (%)5657550.83
Mean prednisolone daily dose (mg)‡7.0±6.26.6±4.57.3±7.60.68
Currently on IS (%)5655580.83
Currently on AZA (%)2414330.047
Currently on MMF (%)2736200.15
Currently on BPLD (%)6574580.18
Need for additional IS therapy (%)4136470.38
Need for additional intravenous CY (>3 g) (%)191420§0.57
Need for RTX (%)111211>0.99
  • *Data on patients alive and not lost to follow-up.

  • †By unpaired t test or Fisher's exact test.

  • ‡Calculated for patients on GC only.

  • §One AZA patient received additional intravenous CY for a neuropsychiatric non-renal flare.

  • AZA, azathioprine; BPLD, blood pressure lowering drug; GC, glucocorticoid; IS, immunosuppressant; CY, cyclophosphamide; MMF, mycophenolate mofetil; RTX, rituximab.